PACIFIC RESEARCH INSTITUTE
If any industry deserves to face antitrust scrutiny, it’s this one. Putting a stop to PBMs’ anticompetitive practices would be far more fruitful than imposing new price controls or other regulations on manufacturers.
The Culprit Impeding Drug Competition Is Not Who The Feds Expected
Previous
Previous
The Big Beautiful Bill Fixes One Drug Problem—But Highlights An Even Bigger One
Next
Next